Gene therapy constructs and methods of use

1. A method for treating a genetic disorder comprising, administering to a subject in need thereof a gene therapy vector or a pharmaceutical composition comprising the gene therapy vector, wherein the gene therapy vector comprises a nucleic acid construct encoding a polypeptide comprising: (a) a therapeutic protein, wherein the therapeutic protein is a lysosomal enzyme; (b) a peptide that binds to the cation-independent mannose 6-phosphate (M6P) receptor (CI-MPR), wherein the peptide is a variant (vIGF2) peptide comprising the sequence of SEQ ID NO: 31; (c) a linker between the therapeutic protein and the peptide that binds CI-MPR; and (d) a signal peptide selected from a binding immunoglobulin protein (BiP) signal peptide and a Gaussia signal peptide; wherein the genetic disorder is a lysosomal storage disorder.

2. The method of claim 1 , wherein the genetic disorder is selected from the group consisting of aspartylglucosaminuria, Batten disease, cystinosis, Fabry disease, Gaucher disease type I, Gaucher disease type II, Gaucher disease type III, Pompe disease, Tay Sachs disease, Sandhoff disease, metachomatic leukodystrophy, mucolipidosis type I, mucolipidosis type II, mucolipidosis type III, mucolipidosis type IV, Hurler disease, Hunter disease, Sanfilippo disease type A, Sanfilippo disease type B, Sanfilippo disease type C, Sanfilippo disease type D, Morquio disease type A, Morquio disease type B, Maroteau-Lamy disease, Sly disease, Niemann-Pick disease type A, Niemann-Pick disease type B, Niemann-Pick disease type C1, Niemann-Pick disease type C2, Schindler disease type I, Schindler disease type II, adenosine deaminase severe combined immunodeficiency (ADA-SCID), chronic granulomatous disease (CGD), and neuronal ceroid lipofuscinosis.

3. The method of claim 2 , wherein the genetic disorder is Pompe disease.

4. The method of claim 2 , wherein the genetic disorder is neuronal ceroid lipofuscinosis.

5. The method of claim 4 , wherein the genetic disorder is a CLN1 disease.

6. The method of claim 1 , wherein the administering is performed intrathecally, intraocularly, intravitreally, retinally, intravenously, intramuscularly, intraventricularly, intracerebrally, intracerebellarly, intracerebroventricularly, intraperenchymally, subcutaneously, or a combination thereof.

7. The method of claim 6 , wherein the administering is performed intrathecally.

8. The method of claim 1 , wherein the therapeutic protein is selected from the group consisting of alpha-galactosidase A, beta.-glucocerebrosidase, glucocerebrosidase, lysosomal acid lipase, glycosaminoglycan alpha-L-iduronohydrolase, iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase, glycosaminoglycan N-acetylgalactosamine 4-sulfatase, palmitoyl protein thioesterase-1, and alpha-glucosidase.

9. The method of claim 8 , wherein the therapeutic protein is alpha-glucosidase.

10. The method of claim 8 , wherein the therapeutic protein is palmitoyl protein thioesterase-1.

11. The method of claim 1 , wherein the nucleic acid construct further comprises a translation initiation sequence.

12. The method of claim 1 , wherein the construct comprises SEQ ID NO:36.

13. The method of claim 1 , wherein the polypeptide comprises SEQ ID NO:23.

14. The method of claim 1 , wherein the construct comprises SEQ ID NO:38.

15. The method of claim 1 , wherein the vIGF2 peptide is at the N-terminus of the polypeptide.

16. The method of claim 1 , wherein the vIGF2 peptide is at the C-terminus of the polypeptide.

17. The method of claim 1 , wherein the linker peptide comprises SEQ ID NO: 18-21 or SEQ ID NO: 33.

18. The method of claim 1 , wherein the gene therapy vector is a virus vector selected from the group consisting of an adenovirus vector, an adeno-associated virus (AAV) vector, a retrovirus vector, a lentivirus vector, a pox virus vector, a vaccinia virus vector, an adenovirus vector, and a herpes virus vector.